• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Scancell CEO on 2025 Milestones and Road ahead

by chantal | Sep 12, 2025 | Investor Presentations

Scancell Financial Year End 2025 Results

by chantal | Sep 11, 2025 | Investor Presentations, Investors, Presentations

Scancell reports Strong Phase 2 Data on iSCIB1+ in Advanced Melanoma

by chantal | Jul 24, 2025 | Immunobody, Investor Presentations, iSCIB1+

Active Immunotherapy for a Cancer-Free Future

by chantal | Jul 22, 2025 | Immunobody, Investor Presentations, iSCIB1+, SCIB1

Clinical & Corporate Update: Active Immunotherapy for a Cancer-Free Future

by chantal | Jun 25, 2025 | Investor Presentations

Investor Update: 24 April 2025

by chantal | Apr 25, 2025 | Investor Presentations

« Older Entries
Next Entries »

Recent Posts

  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy